The following monoclonal antibodies were used for the characterization of MSCs:
CD45-FITC (BD Biosciences clone HI30, dilution 1:100),
CD34-PE (BD Biosciences clone 581, dilution 1:5),
CD73-PE (BD Biosciences clone AD2, dilution 1:20),
CD90-PE (BD Biosciences clone 5E10, dilution 1:100),
MHCI-PECy7 (BD Biosciences clone G46-2.6, dilution 1:20),
CD80-PECy7 (BD Biosciences clone L307.4, dilution 1:20),
CD105-PE (Serotec clone SN6, dilution 1:10), MCHII-FITC (Biolegend clone L243 at 1:200), and
CD86-AF488 (Biolegend clone IT2.2, dilution 1:20). For staining, the cells were washed with FACS buffer (PBS containing 1% FBS and 0.1 % NaN
3). The antibodies were diluted in 50 μL of FACS buffer, combined with 1 × 10
5 cells/sample and incubated for 30 min at 4 °C. The unbound antibody was removed by washing twice with FACS buffer. The cells were resuspended in FACS buffer for analysis on a
BD FACS Canto. Compensation parameters were established on the FACS Canto using appropriately single stained cells or compensation beads and fluorescence minus one (FMO) controls. Propidium iodide (PI) was used as a viability dye to exclude dead cells and debris from analysis. The data were analyzed using the FlowJo software version 10 (Tree Star Inc, OR, USA) .
Watson L., Chen X.Z., Ryan A.E., Fleming Á., Carbin A., O’Flynn L., Loftus P.G., Horan E., Connolly D., McDonnell P., McNamara L.M., O’Brien T, & Coleman C.M. (2020). Administration of Human Non-Diabetic Mesenchymal Stromal Cells to a Murine Model of Diabetic Fracture Repair: A Pilot Study. Cells, 9(6), 1394.